Cancer Res Treat.  2021 Jul;53(3):621-634. 10.4143/crt.2021.299.

Who Will Benefit from Charged-Particle Therapy?

• Kim KS
• Wu HG

• KMID: 2518385
• DOI: http://doi.org/10.4143/crt.2021.299

Abstract

Charged-particle therapy (CPT) such as proton beam therapy (PBT) and carbon-ion radiotherapy (CIRT) exhibit substantial physical and biological advantages compared to conventional photon radiotherapy. As it can reduce the amount of radiation irradiated in the normal organ, CPT has been mainly applied to pediatric cancer and radioresistent tumors in the eloquent area. Although there is a possibility of greater benefits, high set-up cost and dearth of high level of clinical evidence hinder wide applications of CPT. This review aims to present recent clinical results of PBT and CIRT in selected diseases focusing on possible indications of CPT. We also discussed how clinical studies are conducted to increase the number of patients who can benefit from CPT despite its high cost.

Keyword

Charged-particle therapy; Proton beam therapy; Carbon-ion radiotherapy

Reference

References

1. Seo YS, Kim MS, Kang JK, Jang WI, Kim HJ, Cho CK, et al. The clinical utilization of radiation therapy in Korea between 2011 and 2015. Cancer Res Treat. 2018; 50:345–55.

2. Mohamad O, Sishc BJ, Saha J, Pompos A, Rahimi A, Story MD, et al. Carbon ion radiotherapy: a review of clinical experiences and preclinical research, with an emphasis on DNA damage/repair. Cancers (Basel). 2017; 9:66.

3. Dreher C, Combs SE. Clinical rationale and indications for particle therapy. Guckenberger M, Combs SE, Zips D, editors. Advances in radiotherapy. 44. Basel: Karger Publishers;2018. p. 89–104.

4. Durante M, Orecchia R, Loeffler JS. Charged-particle therapy in cancer: clinical uses and future perspectives. Nat Rev Clin Oncol. 2017; 14:483–95.

5. Rackwitz T, Debus J. Clinical applications of proton and carbon ion therapy. Semin Oncol. 2019; 46:226–32.

6. Schaub L, Harrabi SB, Debus J. Particle therapy in the future of precision therapy. Br J Radiol. 2020; 93:20200183.

7. ASTRO Targeting Cancer Care. Model policies [Internet]. Arlington, VA: American Society for Radiation Oncology;2021. [cited 2021 May 30]. Available from: https://www.astro.org/Daily-Practice/Reimbursement/Model-Policies .

8. Burnet NG, Mackay RI, Smith E, Chadwick AL, Whitfield GA, Thomson DJ, et al. Proton beam therapy: perspectives on the National Health Service England clinical service and research programme. Br J Radiol. 2020; 93:20190873.

9. Health Council of the Netherlands. Proton radiotherapy. Hague: Health Council of the Netherlands;2009.

10. Huh SJ, Nishimura T, Park W, Onishi H, Ahn YC, Nakamura K. Current status and comparison of national health insurance systems for advanced radiation technologies in Korea and Japan. Radiat Oncol J. 2020; 38:170–5.

11. Parikh-Patel A, Morris CR, Maguire FB, Daly ME, Kizer KW. A population-based assessment of proton beam therapy utilization in California. Am J Manag Care. 2020; 26:e28–35.

12. Yock TI, Bhat S, Szymonifka J, Yeap BY, Delahaye J, Donaldson SS, et al. Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. Radiother Oncol. 2014; 113:89–94.

13. Yock TI, Yeap BY, Ebb DH, Weyman E, Eaton BR, Sherry NA, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncol. 2016; 17:287–98.

14. Tabrizi S, Yeap BY, Sherman JC, Nachtigall LB, Colvin MK, Dworkin M, et al. Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. Radiother Oncol. 2019; 137:95–101.

15. Sethi RV, Shih HA, Yeap BY, Mouw KW, Petersen R, Kim DY, et al. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer. 2014; 120:126–33.

16. Gragoudas ES. Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture. Invest Ophthalmol Vis Sci. 2006; 47:4666–73.

17. Kim TW, Choi E, Park J, Shin DH, Jung SK, Seok S, et al. Clinical outcomes of proton beam therapy for choroidal melanoma at a single institute in Korea. Cancer Res Treat. 2018; 50:335–44.

18. Wang Z, Nabhan M, Schild SE, Stafford SL, Petersen IA, Foote RL, et al. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2013; 86:18–26.

19. Tsuji H, Ishikawa H, Yanagi T, Hirasawa N, Kamada T, Mizoe JE, et al. Carbon-ion radiotherapy for locally advanced or unfavorably located choroidal melanoma: a phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys. 2007; 67:857–62.

20. Pommier P, Liebsch NJ, Deschler DG, Lin DT, McIntyre JF, Barker FG 2nd, et al. Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg. 2006; 132:1242–9.

21. Mendenhall WM, Dagan R, Bryant CM, Amdur RJ. Definitive radiotherapy for skin and adenoid cystic carcinoma with perineural invasion. J Neurol Surg B Skull Base. 2016; 77:169–72.

22. Jensen AD, Poulakis M, Nikoghosyan AV, Welzel T, Uhl M, Federspil PA, et al. High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years’ experience with raster-scanned carbon ion therapy. Radiother Oncol. 2016; 118:272–80.

23. Sulaiman NS, Demizu Y, Koto M, Saitoh JI, Suefuji H, Tsuji H, et al. Multicenter study of carbon-ion radiation therapy for adenoid cystic carcinoma of the head and neck: subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN). Int J Radiat Oncol Biol Phys. 2018; 100:639–46.

24. Naganawa K, Koto M, Takagi R, Hasegawa A, Ikawa H, Shimozato K, et al. Long-term outcomes after carbon-ion radiotherapy for oral mucosal malignant melanoma. J Radiat Res. 2017; 58:517–22.

25. Koto M, Demizu Y, Saitoh JI, Suefuji H, Tsuji H, Okimoto T, et al. Multicenter study of carbon-ion radiation therapy for mucosal melanoma of the head and neck: subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN). Int J Radiat Oncol Biol Phys. 2017; 97:1054–60.

26. Patel SH, Wang Z, Wong WW, Murad MH, Buckey CR, Mohammed K, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncol. 2014; 15:1027–38.

27. Suefuji H, Koto M, Demizu Y, Saitoh JI, Shioyama Y, Tsuji H, et al. A retrospective multicenter study of carbon ion radiotherapy for locally advanced olfactory neuroblastomas. Anticancer Res. 2018; 38:1665–70.

28. Hayashi K, Koto M, Demizu Y, Saitoh JI, Suefuji H, Okimoto T, et al. A retrospective multicenter study of carbon-ion radiotherapy for external auditory canal and middle ear carcinomas. Cancer Med. 2019; 8:51–7.

29. Koto M, Demizu Y, Saitoh JI, Suefuji H, Tsuji H, Okimoto T, et al. Definitive carbon-ion radiation therapy for locally advanced sinonasal malignant tumors: subgroup analysis of a multicenter study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS). Int J Radiat Oncol Biol Phys. 2018; 102:353–61.

30. Seidensaal K, Harrabi SB, Uhl M, Debus J. Re-irradiation with protons or heavy ions with focus on head and neck, skull base and brain malignancies. Br J Radiol. 2020; 93:20190516.

31. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol. 1999; 175(Suppl 2):57–63.

32. Fung V, Calugaru V, Bolle S, Mammar H, Alapetite C, Maingon P, et al. Proton beam therapy for skull base chordomas in 106 patients: a dose adaptive radiation protocol. Radiother Oncol. 2018; 128:198–202.

33. Noel G, Feuvret L, Calugaru V, Dhermain F, Mammar H, Haie-Meder C, et al. Chordomas of the base of the skull and upper cervical spine: one hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol. 2005; 44:700–8.

34. Youn SH, Cho KH, Kim JY, Ha B, Lim YK, Jeong JH, et al. Clinical outcome of proton therapy for patients with chordomas. Radiat Oncol J. 2018; 36:182–91.

35. Indelicato DJ, Rotondo RL, Begosh-Mayne D, Scarborough MT, Gibbs CP, Morris CG, et al. A prospective outcomes study of proton therapy for chordomas and chondrosarcomas of the spine. Int J Radiat Oncol Biol Phys. 2016; 95:297–303.

36. Chen YL, Liebsch N, Kobayashi W, Goldberg S, Kirsch D, Calkins G, et al. Definitive high-dose photon/proton radiotherapy for unresected mobile spine and sacral chordomas. Spine (Phila Pa 1976). 2013; 38:E930–6.

37. Palm RF, Oliver DE, Yang GQ, Abuodeh Y, Naghavi AO, Johnstone PA. The role of dose escalation and proton therapy in perioperative or definitive treatment of chondrosarcoma and chordoma: an analysis of the National Cancer Data Base. Cancer. 2019; 125:642–51.

38. Lu VM, O’Connor KP, Mahajan A, Carlson ML, Van Gompel JJ. Carbon ion radiotherapy for skull base chordomas and chondrosarcomas: a systematic review and meta-analysis of local control, survival, and toxicity outcomes. J Neurooncol. 2020; 147:503–13.

39. Nikoghosyan AV, Karapanagiotou-Schenkel I, Munter MW, Jensen AD, Combs SE, Debus J. Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study. BMC Cancer. 2010; 10:607.

40. Nikoghosyan AV, Rauch G, Munter MW, Jensen AD, Combs SE, Kieser M, et al. Randomised trial of proton vs. carbon ion radiation therapy in patients with low and intermediate grade chondrosarcoma of the skull base, clinical phase III study. BMC Cancer. 2010; 10:606.

41. Uhl M, Welzel T, Jensen A, Ellerbrock M, Haberer T, Jakel O, et al. Carbon ion beam treatment in patients with primary and recurrent sacrococcygeal chordoma. Strahlenther Onkol. 2015; 191:597–603.

42. Demizu Y, Imai R, Kiyohara H, Matsunobu A, Okamoto M, Okimoto T, et al. Carbon ion radiotherapy for sacral chordoma: a retrospective nationwide multicentre study in Japan. Radiother Oncol. 2021; 154:1–5.

43. Mima M, Demizu Y, Jin D, Hashimoto N, Takagi M, Terashima K, et al. Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma. Br J Radiol. 2014; 87:20130512.

44. Imai R, Kamada T, Araki N. Working Group for Bone and Soft Tissue Sarcomas. Carbon ion radiation therapy for unresectable sacral chordoma: an analysis of 188 cases. Int J Radiat Oncol Biol Phys. 2016; 95:322–7.

45. Imai R, Kamada T, Araki N. Working Group for Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas. Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma. Cancer Med. 2018; 7:4308–14.

46. Serizawa I, Kagei K, Kamada T, Imai R, Sugahara S, Okada T, et al. Carbon ion radiotherapy for unresectable retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2009; 75:1105–10.

47. Kamada T, Tsujii H, Tsuji H, Yanagi T, Mizoe JE, Miyamoto T, et al. Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol. 2002; 20:4466–71.

48. Chang JY, Jabbour SK, De Ruysscher D, Schild SE, Simone CB 2nd, Rengan R, et al. Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016; 95:505–16.

49. Iwata H, Demizu Y, Fujii O, Terashima K, Mima M, Niwa Y, et al. Long-term outcome of proton therapy and carbon-ion therapy for large (T2a-T2bN0M0) non-small-cell lung cancer. J Thorac Oncol. 2013; 8:726–35.

50. Bush DA, Cheek G, Zaheer S, Wallen J, Mirshahidi H, Katerelos A, et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Int J Radiat Oncol Biol Phys. 2013; 86:964–8.

51. Ono T, Hareyama M, Nakamura T, Kimura K, Hayashi Y, Azami Y, et al. The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: a single center experience. Radiat Oncol. 2016; 11:56.

52. Kim H, Pyo H, Noh JM, Lee W, Park B, Park HY, et al. Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy. Radiat Oncol. 2019; 14:19.

53. Nakajima M, Yamamoto N, Hayashi K, Karube M, Ebner DK, Takahashi W, et al. Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: a retrospective analysis. Radiat Oncol. 2017; 12:144.

54. Karube M, Yamamoto N, Nakajima M, Yamashita H, Nakagawa K, Miyamoto T, et al. Single-fraction carbon-ion radiation therapy for patients 80 years of age and older with stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2016; 95:542–8.

55. Chi A, Chen H, Wen S, Yan H, Liao Z. Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review and hypothesis-generating meta-analysis. Radiother Oncol. 2017; 123:346–54.

56. Miyasaka Y, Komatsu S, Abe T, Kubo N, Okano N, Shibuya K, et al. Comparison of oncologic outcomes between carbon ion radiotherapy and stereotactic body radiotherapy for early-stage non-small cell lung cancer. Cancers (Basel). 2021; 13:176.

57. Miyamoto T, Yamamoto N, Nishimura H, Koto M, Tsujii H, Mizoe JE, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2003; 66:127–40.

58. Miyamoto T, Baba M, Sugane T, Nakajima M, Yashiro T, Kagei K, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol. 2007; 2:916–26.

59. Miyamoto T, Baba M, Yamamoto N, Koto M, Sugawara T, Yashiro T, et al. Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys. 2007; 67:750–8.

60. Yamamoto N, Miyamoto T, Nakajima M, Karube M, Hayashi K, Tsuji H, et al. A dose escalation clinical trial of single-fraction carbon ion radiotherapy for peripheral stage I non-small cell lung cancer. J Thorac Oncol. 2017; 12:673–80.

61. Ono T, Yamamoto N, Nomoto A, Nakajima M, Isozaki Y, Kasuya G, et al. Long term results of single-fraction carbon-ion radiotherapy for non-small cell lung cancer. Cancers (Basel). 2020; 13:112.

62. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015; 16:187–99.

63. Tucker SL, Liu A, Gomez D, Tang LL, Allen P, Yang J, et al. Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. Radiother Oncol. 2016; 119:495–500.

64. Hoppe BS, Henderson R, Pham D, Cury JD, Bajwa A, Morris CG, et al. A phase 2 trial of concurrent chemotherapy and proton therapy for stage III non-small cell lung cancer: results and reflections following early closure of a single-institution study. Int J Radiat Oncol Biol Phys. 2016; 95:517–22.

65. Oshiro Y, Okumura T, Kurishima K, Homma S, Mizumoto M, Ishikawa H, et al. High-dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II study. J Radiat Res. 2014; 55:959–65.

66. Anzai M, Yamamoto N, Hayashi K, Nakajima M, Nomoto A, Ogawa K, et al. Safety and efficacy of carbon-ion radiotherapy alone for stage III non-small cell lung cancer. Anticancer Res. 2020; 40:379–86.

67. Hayashi K, Yamamoto N, Nakajima M, Nomoto A, Tsuji H, Ogawa K, et al. Clinical outcomes of carbon-ion radiotherapy for locally advanced non-small-cell lung cancer. Cancer Sci. 2019; 110:734–41.

68. Karube M, Yamamoto N, Shioyama Y, Saito J, Matsunobu A, Okimoto T, et al. Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters. J Radiat Res. 2017; 58:761–4.

69. Saitoh JI, Shirai K, Abe T, Kubo N, Ebara T, Ohno T, et al. A phase I study of hypofractionated carbon-ion radiotherapy for stage III non-small cell lung cancer. Anticancer Res. 2018; 38:885–91.

70. Takahashi W, Nakajima M, Yamamoto N, Yamashita H, Nakagawa K, Miyamoto T, et al. A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC). Cancer. 2015; 121:1321–7.

71. Liao Z, Lee JJ, Komaki R, Gomez DR, O’Reilly MS, Fossella FV, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. J Clin Oncol. 2018; 36:1813–22.

72. Brooks ED, Ning MS, Verma V, Zhu XR, Chang JY. Proton therapy for non-small cell lung cancer: the road ahead. Transl Lung Cancer Res. 2019; 8(Suppl 2):S202–S12.

73. Han Y. Current status of proton therapy techniques for lung cancer. Radiat Oncol J. 2019; 37:232–48.

74. Kim JI, Park JM, Wu HG. Carbon ion therapy: a review of an advanced technology. Prog Med Phys. 2020; 31:71–80.

75. Park S, Yoon WS, Rim CH. Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: diverse global viewpoints. World J Gastroenterol. 2020; 26:393–403.

76. Chiba T, Tokuuye K, Matsuzaki Y, Sugahara S, Chuganji Y, Kagei K, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res. 2005; 11:3799–805.

77. Sakurai H, Ishikawa H, Okumura T. Proton beam therapy in Japan: current and future status. Jpn J Clin Oncol. 2016; 46:885–92.

78. Mohamad O, Makishima H, Kamada T. Evolution of carbon ion radiotherapy at the National Institute of Radiological Sciences in Japan. Cancers (Basel). 2018; 10:66.

79. Spychalski P, Kobiela J, Antoszewska M, Blazynska-Spychalska A, Jereczek-Fossa BA, Hoyer M. Patient specific outcomes of charged particle therapy for hepatocellular carcinoma: a systematic review and quantitative analysis. Radiother Oncol. 2019; 132:127–34.

80. Jang WI, Bae SH, Kim MS, Han CJ, Park SC, Kim SB, et al. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: safety and efficacy. Cancer. 2020; 126:363–72.

81. Yoo GS, Yu JI, Park HC. Proton therapy for hepatocellular carcinoma: current knowledges and future perspectives. World J Gastroenterol. 2018; 24:3090–100.

82. Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, et al. Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival. Int J Radiat Oncol Biol Phys. 2019; 105:64–72.

83. Sugahara S, Oshiro Y, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2010; 76:460–6.

84. Kimura K, Nakamura T, Ono T, Azami Y, Suzuki M, Wada H, et al. Clinical results of proton beam therapy for hepatocellular carcinoma over 5 cm. Hepatol Res. 2017; 47:1368–74.

85. Shibuya K, Ohno T, Katoh H, Okamoto M, Shiba S, Koyama Y, et al. A feasibility study of high-dose hypofractionated carbon ion radiation therapy using four fractions for localized hepatocellular carcinoma measuring 3cm or larger. Radiother Oncol. 2019; 132:230–5.

86. Mizumoto M, Tokuuye K, Sugahara S, Nakayama H, Fukumitsu N, Ohara K, et al. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys. 2008; 71:462–7.

87. Imada H, Kato H, Yasuda S, Yamada S, Yanagi T, Kishimoto R, et al. Comparison of efficacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis. Radiother Oncol. 2010; 96:231–5.

88. Yoo GS, Yu JI, Park HC, Hyun D, Jeong WK, Lim HY, et al. Do biliary complications after proton beam therapy for perihilar hepatocellular carcinoma matter? Cancers (Basel). 2020; 12:2395.

89. Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, et al. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol. 2009; 185:782–8.

90. Kim DY, Park JW, Kim TH, Kim BH, Moon SH, Kim SS, et al. Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis. Radiother Oncol. 2017; 122:122–9.

91. Lee SU, Park JW, Kim TH, Kim YJ, Woo SM, Koh YH, et al. Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol. 2014; 190:806–14.

92. Komatsu S, Fukumoto T, Demizu Y, Miyawaki D, Terashima K, Niwa Y, et al. The effectiveness of particle radiotherapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. J Gastroenterol. 2011; 46:913–20.

93. Nakayama H, Sugahara S, Fukuda K, Abei M, Shoda J, Sakurai H, et al. Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract. Int J Radiat Oncol Biol Phys. 2011; 80:992–5.

94. Kato H, Tsujii H, Miyamoto T, Mizoe JE, Kamada T, Tsuji H, et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys. 2004; 59:1468–76.

95. Shiba S, Abe T, Shibuya K, Katoh H, Koyama Y, Shimada H, et al. Carbon ion radiotherapy for 80 years or older patients with hepatocellular carcinoma. BMC Cancer. 2017; 17:721.

96. Kim TH, Park JW, Kim BH, Oh ES, Youn SH, Moon SH, et al. Phase II study of hypofractionated proton beam therapy for hepatocellular carcinoma. Front Oncol. 2020; 10:542.

97. Kasuya G, Kato H, Yasuda S, Tsuji H, Yamada S, Haruyama Y, et al. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: combined analyses of 2 prospective trials. Cancer. 2017; 123:3955–65.

98. Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, et al. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial. J Hepatol. 2021; 74:603–12.

99. Bush DA, Smith JC, Slater JD, Volk ML, Reeves ME, Cheng J, et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. Int J Radiat Oncol Biol Phys. 2016; 95:477–82.

100. Shiba S, Shibuya K, Katoh H, Kaminuma T, Miyazaki M, Kakizaki S, et al. A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study. Radiat Oncol. 2019; 14:137.

101. Yasuda S, Kato H, Imada H, Isozaki Y, Kasuya G, Makishima H, et al. Long-term results of high-dose 2-fraction carbon ion radiation therapy for hepatocellular carcinoma. Adv Radiat Oncol. 2020; 5:196–203.

102. Makita C, Nakamura T, Takada A, Takayama K, Suzuki M, Ishikawa Y, et al. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma. Radiat Oncol. 2014; 9:26.

103. Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-Institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2016; 34:460–8.

104. Kasuya G, Terashima K, Shibuya K, Toyama S, Ebner DK, Tsuji H, et al. Carbon-ion radiotherapy for cholangiocarcinoma: a multi-institutional study by and the Japan Carbon-ion Radiation Oncology Study Group (J-CROS). Oncotarget. 2019; 10:4369–79.

105. Petrelli F, Comito T, Ghidini A, Torri V, Scorsetti M, Barni S. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials. Int J Radiat Oncol Biol Phys. 2017; 97:313–22.

106. Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys. 2016; 94:755–65.

107. Nichols RC Jr, George TJ, Zaiden RA Jr, Awad ZT, Asbun HJ, Huh S, et al. Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. Acta Oncol. 2013; 52:498–505.

108. Terashima K, Demizu Y, Hashimoto N, Jin D, Mima M, Fujii O, et al. A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiother Oncol. 2012; 103:25–31.

109. Hiroshima Y, Fukumitsu N, Saito T, Numajiri H, Murofushi KN, Ohnishi K, et al. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. Radiother Oncol. 2019; 136:37–43.

110. Takatori K, Terashima K, Yoshida R, Horai A, Satake S, Ose T, et al. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. J Gastroenterol. 2014; 49:1074–80.

111. Kim TH, Lee WJ, Woo SM, Kim H, Oh ES, Lee JH, et al. Effectiveness and safety of simultaneous integrated boost-proton beam therapy for localized pancreatic cancer. Technol Cancer Res Treat. 2018; 17:1533033818783879.

112. Sachsman S, Nichols RC Jr, Morris CG, Zaiden R, Johnson EA, Awad Z, et al. Proton therapy and concomitant capecitabine for non-metastatic unresectable pancreatic adenocarcinoma. Int J Part Ther. 2014; 1:692–701.

113. Jethwa KR, Tryggestad EJ, Whitaker TJ, Giffey BT, Kazemba BD, Neben-Wittich MA, et al. Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes. Adv Radiat Oncol. 2018; 3:314–21.

114. Rutenberg MS, Nichols RC. Proton beam radiotherapy for pancreas cancer. J Gastrointest Oncol. 2020; 11:166–75.

115. Dell’Oro M, Short M, Wilson P, Bezak E. Clinical limitations of photon, proton and carbon ion therapy for pancreatic cancer. Cancers (Basel). 2020; 12:163.

116. Kawashiro S, Yamada S, Okamoto M, Ohno T, Nakano T, Shinoto M, et al. Multi-institutional study of carbon-ion radiotherapy for locally advanced pancreatic cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1403 Pancreas. Int J Radiat Oncol Biol Phys. 2018; 101:1212–21.

117. Shinoto M, Terashima K, Suefuji H, Matsunobu A, Toyama S, Fukunishi K, et al. A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer. Radiother Oncol. 2018; 129:333–9.

118. Shinoto M, Yamada S, Terashima K, Yasuda S, Shioyama Y, Honda H, et al. Carbon ion radiation therapy with concurrent gemcitabine for patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2016; 95:498–504.

119. Shinoto M, Yamada S, Yasuda S, Imada H, Shioyama Y, Honda H, et al. Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer. 2013; 119:45–51.

120. Kawashiro S, Yamada S, Isozaki Y, Nemoto K, Tsuji H, Kamada T. Carbon-ion radiotherapy for locoregional recurrence after primary surgery for pancreatic cancer. Radiother Oncol. 2018; 129:101–4.

121. Kawashiro S, Mori S, Yamada S, Miki K, Nemoto K, Tsuji H, et al. Dose escalation study with respiratory-gated carbon-ion scanning radiotherapy using a simultaneous integrated boost for pancreatic cancer: simulation with four-dimensional computed tomography. Br J Radiol. 2017; 90:20160790.

122. Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018; 4:963–9.

123. Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020; 38:1763–73.

124. Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. 2019; 5:1020–7.

125. Hong TS, Lennerz JK, Wo JY, Ulysse C, Yeap BY, Clark JW, et al. Long term follow-up of a phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (Preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC). Int J Radiat Oncol Biol Phys. 2020; 108(3 Suppl):S151.

126. Hong TS, Wo JY, Jiang W, Yeap BY, Clark JW, Ryan DP, et al. Phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC). J Clin Oncol. 2017; 35(15 Suppl):4118.

127. Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, et al. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014; 89:830–8.

128. Vitolo V, Cobianchi L, Brugnatelli S, Barcellini A, Peloso A, Facoetti A, et al. Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study. BMC Cancer. 2019; 19:922.

129. Iwata H, Ishikawa H, Takagi M, Okimoto T, Murayama S, Akimoto T, et al. Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group. Cancer Med. 2018; 7:677–89.

130. Mendenhall NP, Hoppe BS, Nichols RC, Mendenhall WM, Morris CG, Li Z, et al. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014; 88:596–602.

131. Takagi M, Demizu Y, Terashima K, Fujii O, Jin D, Niwa Y, et al. Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med. 2017; 6:2234–43.

132. Bryant C, Smith TL, Henderson RH, Hoppe BS, Mendenhall WM, Nichols RC, et al. Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2016; 95:422–34.

133. Ha B, Cho KH, Lee KH, Joung JY, Kim YJ, Lee SU, et al. Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation. Radiat Oncol. 2019; 14:4.

134. Ishikawa H, Tsuji H, Kamada T, Akakura K, Suzuki H, Shimazaki J, et al. Carbon-ion radiation therapy for prostate cancer. Int J Urol. 2012; 19:296–305.

135. Nomiya T, Tsuji H, Kawamura H, Ohno T, Toyama S, Shioyama Y, et al. A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: a report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS). Radiother Oncol. 2016; 121:288–93.

136. Ishikawa H, Tsuji H, Kamada T, Yanagi T, Mizoe JE, Kanai T, et al. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol. 2006; 81:57–64.

137. Nomiya T, Tsuji H, Maruyama K, Toyama S, Suzuki H, Akakura K, et al. Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks. Br J Cancer. 2014; 110:2389–95.

138. Okada T, Tsuji H, Kamada T, Akakura K, Suzuki H, Shimazaki J, et al. Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20 to 16 fractions. Int J Radiat Oncol Biol Phys. 2012; 84:968–72.

139. Ishikawa H, Tsuji H, Murayama S, Sugimoto M, Shinohara N, Maruyama S, et al. Particle therapy for prostate cancer: The past, present and future. Int J Urol. 2019; 26:971–9.

140. Mohamad O, Tabuchi T, Nitta Y, Nomoto A, Sato A, Kasuya G, et al. Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study. Lancet Oncol. 2019; 20:674–85.

141. Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay EJ, et al. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: a propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018; 128:154–60.

142. Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, et al. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. J Clin Oncol. 2020; 38:1569–79.

143. Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, et al. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis. Int J Radiat Oncol Biol Phys. 2017; 99:667–76.

144. Akutsu Y, Yasuda S, Nagata M, Izumi Y, Okazumi S, Shimada H, et al. A phase I/II clinical trial of preoperative short-course carbon-ion radiotherapy for patients with squamous cell carcinoma of the esophagus. J Surg Oncol. 2012; 105:750–5.

145. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001; 345:638–46.

146. Venkatesulu BP, Giridhar P, Malouf TD, Trifletti DM, Krishnan S. A systematic review of the role of carbon ion radiation therapy in recurrent rectal cancer. Acta Oncol. 2020; 59:1218–23.

147. Shinoto M, Yamada S, Okamoto M, Shioyama Y, Ohno T, Nakano T, et al. Carbon-ion radiotherapy for locally recurrent rectal cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1404 Rectum. Radiother Oncol. 2019; 132:236–40.

148. Habermehl D, Wagner M, Ellerbrock M, Buchler MW, Jakel O, Debus J, et al. Reirradiation using carbon ions in patients with locally recurrent rectal cancer at HIT: first results. Ann Surg Oncol. 2015; 22:2068–74.

149. Barcellini A, Vitolo V, Cobianchi L, Peloso A, Vanoli A, Mirandola A, et al. Re-irradiation With carbon ion radiotherapy for pelvic rectal cancer recurrences in patients previously irradiated to the pelvis. In Vivo. 2020; 34:1547–53.

150. Cai X, Du Y, Wang Z, Li P, Yu Z, Zhang Q, et al. The role of carbon ion radiotherapy for unresectable locally recurrent rectal cancer: a single institutional experience. Radiat Oncol. 2020; 15:209.

151. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013; 368:987–98.

152. Mailhot Vega RB, Ishaq O, Raldow A, Perez CA, Jimenez R, Scherrer-Crosbie M, et al. Establishing cost-effective allocation of proton therapy for breast irradiation. Int J Radiat Oncol Biol Phys. 2016; 95:11–8.

153. Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer. 2016; 122:1483–501.

154. Zietman AL. Too big to fail? The current status of proton therapy in the USA. Clin Oncol (R Coll Radiol). 2018; 30:271–3.

155. Zietman AL. Can proton therapy be considered a standard of care in oncology? Lessons from the United States. Br J Cancer. 2019; 120:775–6.

156. Widder J, van der Schaaf A, Lambin P, Marijnen CA, Pignol JP, Rasch CR, et al. The quest for evidence for proton therapy: model-based approach and precision medicine. Int J Radiat Oncol Biol Phys. 2016; 95:30–6.